Clinical Trials on Prevention of Meningococcal Infection

Total 3039 results

GlaxoSmithKline

Completed

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

Infections, Meningococcal

Australia
GlaxoSmithKline

Completed

Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine

Infections, Meningococcal

Germany, Austria, Greece
GlaxoSmithKline

Completed

Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects

Infections, Meningococcal

Lebanon
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds

Infections, Meningococcal

Thailand, Panama, Philippines
GlaxoSmithKline

Completed

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Infections, Meningococcal

Philippines, Lebanon
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects

Infections, Meningococcal

Taiwan, Philippines, India
GlaxoSmithKline

Completed

Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612

Infections, Meningococcal

Denmark
GlaxoSmithKline

Completed

Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs

Infections, Meningococcal

Lebanon
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

Infections, Meningococcal
GlaxoSmithKline

Completed

Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years

Infections, Meningococcal

Belgium
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)

Prevention of : Herpes-Zoster
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization

Prevention of COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization

Prevention of COVID-19

China
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
GlaxoSmithKline

Completed

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

Meningococcal Disease

Korea, Republic of
Novartis Vaccines

Completed

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Meningococcal Disease

United States, Poland
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Meningococcal Disease

Italy
Novartis Vaccines

Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Meningococcal Disease

Austria, Finland, Germany, Italy, Czech Republic
Leiden University Medical Center

Completed

Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines

Meningococcal Disease

Netherlands
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Completed

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

Meningococcal Sero-type C Infection

Canada
Sebela Women's Health Inc.

Completed

Comparative Study of the VeraCept Low-Dose Intrauterine Copper Contraceptive vs. the TCu380 Copper IUD

Prevention of Pregnancy

Dominican Republic
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Infections, Meningococcal

United States, Australia, Finland, Poland, Belgium, Brazil, Sweden, Turkey
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

Infections, Meningococcal

Philippines, Saudi Arabia
GlaxoSmithKline

Completed

Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Infections, Meningococcal

Sweden, Denmark
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612

Infections, Meningococcal

Philippines, India
GlaxoSmithKline

Completed

Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine

Infections, Meningococcal

Germany, Austria
GlaxoSmithKline

Completed

Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

Infections, Meningococcal

Belgium
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Infections, Meningococcal

United States
Shanghai Cell Therapy Group Co.,Ltd

Not yet recruiting

The Exploratory Study on the Biological Function of Dendritic Cells In Vivo Supported by Nicotinamide Mononucleotide (Vital NAD)

Postoperative Prevention of Tumor

China
Center for Vaccine Development - Mali
University College, London; University of Oxford; Public Health England; University... and other collaborators

Recruiting

A Human Controlled Infection Study With Neisseria Lactamica in Malian Adults

Meningitis, Meningococcal

Mali
Poitiers University Hospital

Recruiting

Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease (CARACIIM)

Meningococcal Infections

France
GlaxoSmithKline

Completed

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Meningococcal Disease

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

Meningococcal Disease

Italy
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
Novartis Vaccines
Novartis

Completed

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Meningococcal Disease

Canada, United Kingdom
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
London School of Hygiene and Tropical Medicine
Bill and Melinda Gates Foundation

Withdrawn

A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger (VES)

Meningococcal Disease

Mali, Niger
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
Federal State Budgetary Scientific Institution...

Completed

Testing the Effectiveness and Safety of a Passive Industrial Exoskeleton for the Upper Limb

Prevention of Diseases of the Musculoskeletal System

Russian Federation
GlaxoSmithKline

Completed

Safety of 4CMenB Exposure During Pregnancy

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children

Infections, Meningococcal

Germany, France
GlaxoSmithKline

Completed

Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

Infections, Meningococcal

Germany
GlaxoSmithKline

Completed

Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

Infections, Meningococcal

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Infections, Meningococcal

United States

3

Subscribe